Access to the PPM Journal and newsletters is FREE for clinicians.

Lidocaine Topical Approved for Shingles Pain

March 1, 2018
Non-opioid analgesic patch may relieve post-herpetic neuralgia up to 12 hours.

A PPM Brief

FDA has approved a lidocaine topical from Sorrento Therapeutics (San Diego) and Scilex Pharmaceuticals (San Diego) for the treatment of post-herpetic neuralgia, or post-shingles pain. Called ZTlido, the 1.8% lidocaine topical system is unique in its proprietary adhesion technology—the wearable patch is effective for 12 hours, even during exercise.

Molecular structure of lidocaine

“ZTlido was designed to solve a problem that is commonly reported with transdermal/topical patches: they don’t stay on. Based on the adhesion study results with ZTlido, we believe that ZTlido product will be welcomed by healthcare providers, patients and payers who are looking for an effective and efficient, local pain treatment,” said Dr. Henry Ji, Chairman and CEO of Sorrento and Scilex, in a news release

Practical Pain Management Executive Editorial Advisor Jeff Gudin, MD, has been following topical analgesics for some time. He commented in the announcement that, “Topical lidocaine is an important option for healthcare providers to have in their armamentarium for treating PHN, a difficult-to-treat neuropathic pain…. The Centers for Disease Control and Prevention’s guideline of non-opioid treatments for chronic pain recognizes topical lidocaine as an alternative first-line therapy. ZTlido now offers providers and patients this option.”

Sorrento and Scilex plan to pursue the efficacy of their topical technology with other active pharmaceutical ingredients as well.


Last updated on: March 2, 2018
Continue Reading:
Topical Analgesics May Reduce or Eliminate Prescribed Opioid Use
close X